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Physiology and biochemistry of endothelial function in children with
chronic renal failure. Premature atherosclerosis is a major cause of
morbidity and mortality in chronic renal failure (CRF). Endothelial
dysfunction is a key early event in atherogencsis. The aim of this study was
to assess the effect of CRF on endothelial function using physiolcgical and
biochemical measures. To focus on the effect of CRF itself, 23 children
(matched with 23 controls for age and vessel diameter) were selected
because they were normotensive, had normal total cholesterol (TC) levels,
and were not on vasoactive drugs. Their mean (range) age was 12.0 (7.8 to
17.0) years; GFR 17.5 (8.8 to 34.5) ml/min/1.73 rn2 The physiology of
endothelial function in the brachial artery was assessed using high
resolution ultrasound by measuring its diameter at rest, during reactive
hyperemia (endothelium dependent dilation) and after sublingual glyceryl
trinitrate (GTN: endothehum independent dilation). Nitric oxide (NO)
metaholites and endogenous NO synthetase (eNOS) inhibitors were
measured as an assessment of endothelial metabolism. Brachial artery
dilation to flow IFMI), mean (si.u)%] was reduced in CRF to 4.9 (0.6) and
controls 8.6 (0.6). P < 0.0001. In contrast, the response to GTN was
similar in both groups: CRF 25.1 (1.6), controls 23.3 (1.2), P = 0.31. There
was no difference in TC, low density lipoprotein (LDL) or high density
lipoproteio (HDL) between the patients and the controls. Triglycerides
(TG) were higher in the patients hut within the normal range. Antibodies
against oxidized I.DL (ox-1.DL) were high in CRF. Endogenous NOS
inhibitors were high in CRF, and intermediate NO metabolites were low.
'[here was no correlation between FMD of the brachial artery and lipid
subtractions, or with NO metaholites or eNOS inhibitors. Endothelium
dependent dilation of the brachial artery is impaired in children with CRF
who do not have co-existing risk factors for atherosclerosis. This may
represent early evidence of atherogenic vascular disease.
Premature atherosclerosis is a major cause of morbidity in
adults with chronic renal failure (CRF), and is responsible for a
mortality rate ten times greater than in the normal population [1].
An increasing number of children with CRF are surviving to
adulthood, both because of advances in dialysis and transplanta-
tion, and because treatment is being extended to younger patients.
Their long-term morbidity and mortality are uncertain, but they
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might he expected to have similar vascular complications to adults
with CRF, at an even earlier age.
Although the clinical manifestations of atherosclerosis do not
usually occur before adulthood, the process begins in childhood
[2]. Endothelial dysfunction is a key early event that precedes the
formation of atherosclerotic plaques, and results in reduced
bioavailability of nitric oxide (NO), which may be an important
anti-atherogenic agent [3]. In CRF, abnormal endothelial func-
tion and NO activity may result from both the metabolic conse-
quences of CRF, such as reduced clearance of endogenous NO
synthetase (eNOS) inhibitors [4, 5] and increased oxidative stress
[6], as well as from the presence of other classical risk factors such
as hyperlipidemia and hypertension [1].
We have developed a non-invasive technique using high reso-
lotion ultrasound to assess vascular reactivity in the conduit
arteries of the systemic circulation, which can be used to study
endothelial function from as early as the first decade of life [7].
We have previously shown that endothelial dysfunction may occur
before clinical evidence of vascular disease in subjects with
hypercholesterolemia [8], diabetes [9] and in cigarette smokers
[10].
In the current study we have examined the influence of CRF on
endothelial function in young subjects. In order to avoid con-
founding variables, we purposefully selected subjects with CRF
who were not smokers, hypertensive, hypercholesterolemic or
diabetic, and were not receiving vasoactive drug therapy.
Our findings suggest that CRF has a direct adverse effect on
endothelial function in this young patient group. This may influ-
ence later morbidity and mortality from large vessel atheroscle-
rotic disease independently of other risk factors.
METHODS
Patients
Twenty-three children (18 boys), aged 7.8 to 17.0 years (median
and mean 12.0), with CRF on conservative management, none of
whom were on maintenance dialysis [mean (range) glomerular
filtration rate (GFR) 17.5 (8.8 to 34.5) ml/min/1.73 m2], were
studied. Their diagnoses were renal dysplasia (19), reflux ne-
phropathy (2), Alport's syndrome (1) and focal glomerulosclerosis
(1). They were selected from an outpatient population because
they were normotensive [mean (sEM) systolic blood pressure SD
score (BPSDS) for age —0.04 (0.15), diastolic —0.11(0.18)]; with
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plasma total cholesterol (TC) < 5.2 mmol/liter and low density
lipoprotein (LDL) < 3.3 mmol/litcr; were not diabetic or ne-
phrotic [mean (sEM) serum albumin 42.9 (0.6) g/liter, 24-hr
protein excretion 0.85 (0.2) g/liter]; and were not taking vasoactive
or lipid-lowering medications. They were matched with 23 control
subjects (friends or relatives of hospital staff) for age and brachial
artery diameter. Twenty of the controls were gender matched with
the CRF patients (87%). Ten boys and 3 girls in the CRF group,
compared to 9 boys and 4 girls in the controls were over the
normal age for onset of puberty (over 11 years in boys and 10
years in girls).
Plasma nitrite and nitrate (NO oxidation products), high and
low molecular weight nitrosothiols (intermediate metabolites of
NO), eNOS inhibitors [asymmetrical dimcthylarginine (ADMA)
and symmetrical dimethylarginine (SDMA)] in the CRF patients
were compared to values from 6 control children, aged 6 to 16
(median 11 years), who were having blood taken for family genetic
screening of non-cardiac abnormalities. Plasma TC, triglycerides
(TG), LDL and high density lipoprotein (HDL) were measured in
the CRF group and in 12 of the controls who were willing to have
blood tests. Other lipid subfractions such as Apo Al, ApoB,
lipoprotein(a) [Lp(a)J and antibodies against oxidized LDL (ox-
LDL) were measured in the CRF group. All blood samples were
taken after an overnight fast (although tap water was allowed),
were immediately centrifuged, and the plasma was stored at
—70°C. Each subject and/or their parents gave informed consent
to the study, which was approved by the Local Committee on
Ethical Practice.
Endothelial function study
Endothelial and smooth muscle function were studied non-
invasively by examining brachial artery responses to endothelial
dependent and independent stimuli as we have previously re-
ported [71. Serial diameter changes were measured at rest, in
response to reactive hyperemia (with increased flow producing
endothelial dependent vasodilatation), again at rest, and finally
after sublingual glyceryl trinitrate (GTN), which is an endothelial
independent vasodilator. All subjects were scanned in a supine
position following a 10-minute rest period. A high resolution
B-mode ultrasound image of the brachial artery was obtained in a
longitudinal section, 5 to 10 cm above the antecubital fossa, using
a 7 MHz linear array transducer and Acuson 128XP/10 system
(Acuson, Mountain View, CA, USA), connected to a wall-
tracking system (Ingenious Systems, Netherlands) allowing accu-
rate on line diameter measurements. The center of the artery was
identified when the clearest picture of the anterior and posterior
vessel wall layers was obtained. Depth and gain settings were set
to optimize the lumen/arterial wall interface, and machine oper-
ating parameters were not changed throughout the study. The
arm remained in the same position and a satisfactory transducer
position was maintained using a stereotactic clamp. Al! the
ultrasound scan data were recorded on superVHS video for later
flow analysis and all scans were performed by the same operator.
To measure the brachial artery diameter an M-line was placed
perpendicular to the vessel walls on the B-mode image, the
radio-frequency signals from the M-mode output were then
relayed to the wall-tracking system. On completion of five seconds
of data acquisition, the first radio-frequency signal was displayed
and electronic markers placed at the vessel wall/lumen interface
and a beat by beat computation of the end diastolic diameter and
mean over 5 to 10 cardiac cycles was obtained. Reproducibility
and repeatability of this method have been previously reported
[11, 12]. A resting scan was recorded and arterial flow velocity was
measured using a pulsed Doppler signal at a 70° angle to the
vessel with the range gate (1.5 mm) in the center of the artery.
Volume blood flow was calculated by multiplying the velocity time
integral of the Doppler flow signal (corrected for angle) by the
heart rate and the vessel cross-sectional area (1rr2). A pneumatic
tourniquet placed around the forearm was then inflated to 300
mm Hg for 4.5 minutes followed by rapid release, inducing
increased flow. The post-hyperemic diameter was measured be-
tween 55 and 65 seconds after cuff deflation. Peak reactive
hyperemia was calculated as the maximal flow change within 15
seconds of cuff deflation divided by the flow during the resting
(baseline) scan reported as percentage increase in flow. A further
reactive hyperemia was calculated in the same way 15 seconds
after cuff release. Since the velocity is taken from the center of the
artery, absolute values may be overestimated, but the relative
values before and after cuff inflation are accurate. A further 10
minutes was allowed for vessel recovery, after which a second
resting scan was recorded. A 400 jg sublingual dose of GTN was
then administered and a final scan was recorded three minutes
later. Flow mediated dilation (FMD) in the brachial artery
following reactive hyperemia and endothelium independent dila-
tion following GTN administration were expressed as percentage
diameter change relative to the first base line scan.
To assess the reproducibility of the ultrasound technique in
CRF, seven of the children were seen on three occasions, all
within four months of the first study.
Lipid analysis
TC was measured using the cholesterol C system high perfor-
mance cholesterol oxidase 4-aminophenazone (CHOD-PAP)
method and TG by glyceryl phosphate oxidase 4-aminophenazone
(GPO-PAP) high performance enzymatic colorimetric test (both
Boehringer Mannheim Diagnostica GmbH, Mannheim, Ger-
many) [131. HDL was measured following precipitation of ApoB
containing lipoproteins and LDL was calculated using the Friede-
wald formula [14]. ApoAl and ApoB were measured using
immunoturbidimetry (Immuno Ltd, Sevenoaks, Kent, UK) [15],
and Lp(a) by enzyme-linked immunosorhent assay (ELISA) (Tm-
muno Ltd) [16]. All assays were validated by the National
External Quality Assessment Scheme. Antibodies against ox-LDL
were measured by ELISA with a 450 nm filter, based on a set of
standardized serum and controls obtained from a 0-lab-ELISA
kit (Biomedica Gruppe, Austria) [171.
Nitric oxide biochemistry
Nitrite and nitrate were measured using high performance
capillary electrophoresis [18]. Nitrosothiols were measured after
separating the plasma into two molecular weight fractions by
ultracentrifugation (5,000 Mwt filter at 5000 g). Mercury salts
were then added to displace the NO from the thiol to generate
nitrite, which was assayed by capillary electrophoresis [181.
ADMA and SDMA were measured by high performance liquid
chromatography using electroehemical detection after prccolumn
derivatization with o-phthalaldehyde (OPA)/b-mercaptoethanol
[19].
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Table 1. Vascular study results in children with CRF and controls
CRF Controls P
Peak reactive hyperemia % 284.4 (23.7) 357.6 (29.3) 0.06
Reactive hypereniia at 262.3 (27.2) 241 (24.5) 0.61
15 seconds %
Vessel size mm 2.9 (0.1) 2.9 (0.1) 0.72
FMD % 4.9 (0.6) 8.6 (0.6) <0.0001
GTN % 25.1 (1.6) 23.3 (1.2) 0.31
Results are expressed as mean (sEM).
Statistics
Descriptive statistics are expressed as mean SEM. The CRF
and control groups were compared using two sample t-tests.
Univariate regression analysis was used to assess the relationship
between the two dependent variables, flow mediated and GTN
induced dilation, and sex, age, vessel size, and TC in all the
children, and with TG, HDL, LDL, ApoAl, ApoB, Lp(a), anti-
bodies against ox-LDL, GFR and NO metabolites in the 23
children with CRF. Variability between results of the high reso-
lution ultrasound technique (repeatability) for the seven patients
who had been studied on more than one occasion was calculated
as ratio of the within subject SD (the square root of the residual
mean square taken from analysis of variance for repeated mea-
sures) to the overall mean. This gives the estimated coefficient of
variation (%). Statistical significance was inferred at a P value
of < 0.05.
RESULTS
Endothelial physiology
There was no difference in resting vessel size, peak reactive
hyperemia, or reactive hyperemia at 15 seconds after cuff release
between CRF and controls (Table 1). However, FMD(%) in CRF
was significantly impaired in comparison to the controls [4.9 (0.6)
vs. 8.6 (0.6), P < 0.00011. In contrast, dilation to GTN did not
differ from the controls [25.1 (1.6) vs. 23.3 (1.2), P = 0.31] (Fig. 1).
Table 2. Nitric oxide biochemistry results
CRF Controls P
Nitrate 100.9 (9.4) 32.1 (4.3) <0.00001
Nitrite p.M 1.2 (0.1) 1.4 (0.2) 0.38
ADMA pM 3.8 (0.4) 0.7 (0.1) 0.001
SDMA psi 1.8 (0.2) 0.3 (0.1) 0.001
Low molecular wt nitrosothiol psi 0.9 (0.1) 1.6 (0.2) 0.02
High molecular wt nitrosothiol psi 2.5 (0.1) 3.4 (0.3) 0.0001
Results are expressed as mean (5EM).
On univariate analysis, there was no correlation between endo-
thelium dependent (FMD) or independent brachial artely dila-
tion and measures of renal function, lipid subfractions and NO
biochemistry.
Study of repeatability
For each child, there was a directionally similar response to
increased flow and to GTN with reproducible failure to dilate to
increased flow on the three study occasions. The mean (range)
across visits of observed FMD was 5.1% (1.5 to 7.3). From analysis
of variance for repeated measures, the estimated coefficient of
variance between visits was 4.3%.
Nitric oxide biochemistry
Plasma nitrate, ADMA and SDMA levels were significantly
elevated in the CRF children (Table 2). There was a significant
inverse correlation between GFR and total dimethylarginines (r =
—0.48,P = 0.03) and SDMA (r = —0.46, P = 0.04), although the
correlation with ADMA was not significant (r = 0.41, P = 0.07).
Nitrite levels however did not differ from controls. Low and high
molecular weight nitrosothiol levels were significantly lower in the
CRF group, and there was a positive correlation between GFR
and low molecular weight nitrosothiol (r = 0.52, P = 0.017).
Although it would be expected that high levels of eNOS
inhibitors might decrease NO production, there was no correla-
tion between ADMA and SDMA and any NO metabolites.
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Fig. 1. Flow mediated (FMD, A) and glyceryl
trinitrate (GTN, B)-induced dilation in the
controls and children with CRF. Horizontal
lines are group means. FMD was significantly
impaired in CRF whereas GTN response was
normal.
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Table 3. Lipid subfractions
Normal
CRF Controls values P
Age years 12.1 (0.5) 12.6 (0.5) 0.53
Total cholesterol mmol/liter 5 (0.1) 4.8 (0.3) <5.2 0.52
Low density lipoprotein 3.0 (0.1) 3.0 (0.2) <3.3 0.97
mmol/liter
High density lipoprotein 1.2 (0.04) 1.2 (0.04) 1.0—2.0 0.92
mmol/liter
Triglycerides mmollliter 1.5 (1.1) 0.76 (1.2) <1.7 0.003
Antibodies against ox- 260 (37.5) <250
LDL ji/mi
ApoAl g/liter 1.6 (0.03) 0.7—1.7
ApoB glliter 1.0 (0.04) 0.6—1.4
Lp(a) g/liter 0.12 (0.07) <0.3
Results are expressed as mean (sEat).
Lipid studies
There was no significant difference between TC, HDL and LDL
levels in the patients and the controls (Table 3). However, TG
levels were higher in the CRF patients and antibodies against
ox-LDL were elevated. GFR correlated with TC (r = 0.50, P =
0.026) and log TG (r = —0.64, P = 0.001) levels even when age
was taken into consideration, but not with other lipid subfractions.
DISCUSSION
Our results show that impaired endothelial function is already
present in the conduit arteries of children with CRF by the first
decade of life. It is likely that this represents an early manifesta-
tion of the atherosclerotic process, which causes important mor-
bidity and mortality in CRF patients in later life [1].
A number of factors may contribute to endothelial dysfunction
in CRF, including dyslipidemia [1], drug therapy, increased oxi-
dative stress [61 and the metabolic consequences of CRF them-
selves. In this study, we set out to determine the influence of CRF
on endothelial function as directly as possible by excluding
patients with hypertension, high plasma cholesterol levels and
those receiving vasoactive drugs. We were able to study endothe-
hal function from a very early stage before acquired risk factors
are likely to play a major role, because of the availability of a
non-invasive technique to examine vascular physiology in conduit
arteries of the systemic circulation. Vasodilation to increased flow
(an endothelium dependent stimulus) is contrasted with response
to GTN (which acts independently of the endothelium). This
technique, both in earlier studies and in the CRF patients, has
been shown to be accurate and reproducible [11, 12]. As FMD in
the brachial artery can be attenuated by intra-arterial infusion of
L-NMMA, it is likely that this method assesses the integrity of the
L-arginine/NO pathway in conduit arteries [20]. Furthermore, a
close correlation has been demonstrated between endothelial
function in the brachial artery, assessed using our method, and
endothelial function in the coronary arteries assessed invasively
using acetyichohine [21].
NO not only acts as a physiological regulator of vascular tone
[22], but it is also an important anti-atherogenic molecule that
inhibits platelet activation, monocyte and endothelial cell inter-
action, and smooth muscle cell proliferation [3]. We chose to use
a physiological measure of NO-dependent endothelial function
because biochemical measurements are difficult to interpret in
CRF due to the effects of abnormal renal clearance. This may
explain the lack of correlation between measures such as nitrite
and nitrate and FMD. Interestingly, nitrosothiols were not af-
fected by renal clearance, and were lowest in the patients with the
lower GFR. S-nitrosothiols, such as S-nitrosocysteine and S-
nitrosoglutathione, are formed either by S-nitrosation of free thiol
groups in the presence of NO [23] or by the reaction of thiols with
peroxynitrite, which is derived from the reaction of NO with
superoxide anion [24]. The nitrosothiols have have been shown to
have biological properties similar to those of NO [25], which may
be released from them [26]. While the biological significance of
S-nitrosothiols remains unclear, they may represent a measure of
NO bioavailability, and low levels in CRF may be one mechanism
whereby NO activity is impaired.
In this study, we did not measure other endothelial dependent
vasoactive compounds, such as endothelin-1 and thromboxane-
A2, because neither has been shown to have a major role in
clinical vascular disease [27]. Our findings of markedly reduced
FMD in young subjects from as early as the first and second
decades of life indicate that CRF may be contributing to endo-
thelial abnormalities in addition to the influences of other vascu-
lar risk factors.
Endothelial dysfunction in CRF may involve abnormalities of
both NO production and breakdown. Decreased synthesis may be
due to the presence of elevated levels of L-arginine analogues
such as ADMA and SDMA in CRF in proportion to its severity,
which competitively antagonize eNOS, accumulate in CRF and
correlate with its progression [4, 5]. They have been shown
experimentally to increase vascular tone [5] and promote early
atherogenic changes [28]. Other molecules that accumulate in
uremia, such as the cytokine IL-8, also inhibit eNOS [4]. Addi-
tionally, in CRF circulating levels of L-arginine, the substrate for
NO production, are reduced [5]. Increased inactivation of NO
may also be important with increased oxidative stress and free
radical production in CRF [6]. While total LDL in our patients
did not differ from the controls (as we had excluded children with
hypercholesteremia), levels of antibodies to ox-LDL were ele-
vated in our patients with CRF. Ox-LDL is a critical factor in
promoting atherogenesis [17] because it interferes with NO
metabolism [29], promotes monocyte chemotaxis and transforma-
tion, and has a direct effect on endothelial cell survival [30]. Thus,
in CRF as in other high risk factor groups, such as insulin-
dependent diabetes melhitus, LDL levels even within the normal
range may have an impact on endothehial function [9]. A similar
situation thus may apply in the children with CRF. In addition, the
higher TG levels in the CRF patients may play a role in
endothelial dysfunction, but their influence on atherogenesis
remains controversial [1].
In conclusion, even young children with CRF, whose outlook
for vascular disease would be expected to be relatively good
because of the absence of hypertension and hypercholesteremia,
have evidence of endothehial dysfunction that may be an early
manifestation of atherogenesis. Detection at this early stage of
abnormal vascular function permits serial studies of interventions
such as risk factor modification, anti-oxidants [31], or L-arginine
administration [8], aiming to prevent or retard large vessel
atherosclerosis, which is such an important contributor to clinical
morbidity and mortality in these patients.
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